Serum samples were obtained from 10 patients with refractory multiple myeloma enrolled on a clinical trial (NCT03502577) of chimeric antigen receptor modified T cells (CAR T) targeting BCMA (Pont et al, 2019). Here, TNFRSF17 is linked to plasma cell myeloma.